Molecular mechanisms of asymmetric RAF dimer activation.

Protein phosphorylation is one of the most common post-translational modifications in cell regulatory mechanisms. Dimerization plays also a crucial role in the kinase activity of many kinases, including RAF, CDK2 (cyclin-dependent kinase 2) and EGFR (epidermal growth factor receptor), with heterodimers often being the most active forms. However, the structural and mechanistic details of how phosphorylation affects the activity of homo- and hetero-dimers are largely unknown. Experimentally, synthesizing protein samples with fully specified and homogeneous phosphorylation states remains a challenge for structural biology and biochemical studies. Typically, multiple changes in phosphorylation lead to activation of the same protein, which makes structural determination methods particularly difficult. It is also not well understood how the occurrence of phosphorylation and dimerization processes synergize to affect kinase activities. In the present article, we review available structural data and discuss how MD simulations can be used to model conformational transitions of RAF kinase dimers, in both their phosphorylated and unphosphorylated forms.

[1]  W. Kolch,et al.  Raf family kinases: old dogs have learned new tricks. , 2011, Genes & cancer.

[2]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[3]  Francesco Luigi Gervasio,et al.  New insights in protein kinase conformational dynamics. , 2012, Current topics in medicinal chemistry.

[4]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[5]  Tony Hunter,et al.  Why nature chose phosphate to modify proteins , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[6]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[7]  Alma L. Burlingame,et al.  A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK , 2011, Nature.

[8]  Susan S. Taylor,et al.  Evolution of the eukaryotic protein kinases as dynamic molecular switches , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[9]  C. Vinson,et al.  Classification of Human B-ZIP Proteins Based on Dimerization Properties , 2002, Molecular and Cellular Biology.

[10]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[11]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[12]  Ron Bose,et al.  Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.

[13]  Arieh Warshel,et al.  Why nature really chose phosphate , 2013, Quarterly Reviews of Biophysics.

[14]  Matthew P. Jacobson,et al.  Conformational Changes in Protein Loops and Helices Induced by Post-Translational Phosphorylation , 2006, PLoS Comput. Biol..

[15]  M. Palcic,et al.  Structural and mechanistic basis for a novel mode of glycosyltransferase inhibition , 2010, Nature chemical biology.

[16]  Tsonwin Hai,et al.  Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Francesco Luigi Gervasio,et al.  Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase , 2013, Proceedings of the National Academy of Sciences.

[18]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[19]  Anton Arkhipov,et al.  Architecture and Membrane Interactions of the EGF Receptor , 2013, Cell.

[20]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[21]  Ron Bose,et al.  Inhibition of the EGF Receptor by Binding to an Activating Kinase Domain Interface , 2007, Nature.

[22]  R. Bayliss,et al.  On the molecular mechanisms of mitotic kinase activation , 2012, Open Biology.

[23]  Gennady Verkhivker,et al.  Computational Modeling of Allosteric Communication Reveals Organizing Principles of Mutation-Induced Signaling in ABL and EGFR Kinases , 2011, PLoS Comput. Biol..

[24]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[25]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[26]  Walter Thiel,et al.  Nobel 2013 Chemistry: Methods for computational chemistry , 2013, Nature.

[27]  G. Rastelli,et al.  αC helix displacement as a general approach for allosteric modulation of protein kinases. , 2013, Drug discovery today.

[28]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[29]  Martin Olbrot,et al.  Characterization of Ser338 Phosphorylation for Raf-1 Activation* , 2008, Journal of Biological Chemistry.

[30]  F. McCormick,et al.  RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. , 2013, Cancer cell.

[31]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[32]  Giulio Superti‐Furga,et al.  Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.

[33]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[34]  A. Velázquez‐Campoy,et al.  The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor. , 2013, Angewandte Chemie.

[35]  Albert C. Pan,et al.  Transitions to catalytically inactive conformations in EGFR kinase , 2013, Proceedings of the National Academy of Sciences.

[36]  Susan S. Taylor,et al.  Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers , 2013, Cell.

[37]  Àngels González-Lafont,et al.  A QM/MM study of the phosphoryl transfer to the Kemptide substrate catalyzed by protein kinase A. The effect of the phosphorylation state of the protein on the mechanism. , 2011, Physical chemistry chemical physics : PCCP.

[38]  John Kuriyan,et al.  A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.

[39]  Guillaume Thibault,et al.  The AAA+ superfamily of functionally diverse proteins , 2008, Genome Biology.

[40]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[41]  A. Wilkinson,et al.  AAA+ superfamily ATPases: common structure–diverse function , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[42]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[43]  Susan S. Taylor,et al.  Insights into the Phosphoryl Transfer Catalyzed by cAMP-Dependent Protein Kinase: An X-ray Crystallographic Study of Complexes with Various Metals and Peptide Substrate SP20 , 2013, Biochemistry.

[44]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[45]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[46]  John Kuriyan,et al.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 , 2009, Proceedings of the National Academy of Sciences.

[47]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[48]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[49]  F. Westheimer.  Why nature chose phosphates. , 1987, Science.